MedinCell Announces Successful Recruitment for Phase 3 Clinical Study of F14 (mdc-CWM), a First-in-Class Localized Treatment for Post-Knee Replacement Pain Relief
– Recruitment is complete after randomization of 151 patients across seven centers in the United States
– The study which started in November 2022 is progressing as planned with efficacy results expected in the first quarter of 2024
– F14 (mdc-CWM) is an extended-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered into the joint at the time of knee replacement
– F14 (mdc-CWM) aims to aid patient recovery by relieving pain by treating inflammation thereby accelerating improvement in knee motor skills and potentially reducing the need for addictive opioids
– F14 (mdc-CWM) is the third product using MedinCell’s proprietary BEPO® technology to reach or complete a Phase 3 clinical trial